SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma

• Hoofdauteurs: Pan Zhou (Auteur), Mengyu Xiao (Auteur), Weiya Li (Auteur), Xiaobai Sun (Auteur), Yanliang Bai (Auteur), Feiying Meng (Auteur), Zunmin Zhu (Auteur), Weiping Yuan (Auteur), Kai Sun (Auteur)
• Formaat: Boek
• Gepubliceerd in: Frontiers Media S.A., 2022-04-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Multiple myeloma (MM) is a plasma cell malignancy that remains incurable. The protein tyrosine phosphatase SHP2 is a central node regulating RAS/mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase (ERK) signaling pathway which plays a crucial role in the pathogenesis and pr...